Jubilant announces 15% rise in Beta Picoline, 3-Cyanopyridine and Vitamin B3 price

Jubilant Life Sciences announces a price increase of up to 15 per cent for its Beta Picoline, 3-Cyanopyridine and Vitamin B3 (Niacin & Niacinamide) with an immediate effect, for non-contract customers as well as wherever existing contracts permit.

Jubilant Life Sciences, a global leader in the pyridine, picolines as well as nutrition industry, is an integrated global pharmaceutical and also a life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions. The company’s Pharmaceuticals segment, through its wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacturing and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products as well as Contract Manufacturing of Sterile and Non-sterile products through 6 USFDA approved manufacturing facilities in India, USA and Canada.

Post the regulatory filing of this update by the company on the stock exchanges, Jubilant share price saw a drop of almost 2.86 per cent or 17.75 points. It is currently trading at Rs 602.85 apiece on NSE at 2.35 PM. The intraday high of the share so far was reported at Rs 626.55 and the intraday low is Rs 598.00.

Jubilant share price opened at Rs 622.50, about 2 points higher than its previous closing of Rs 620.60.

A total of 3,94,099 shares of the company have exchanged hands on the counter of NSE aggregating to a total value of Rs 2,406.60. The 20 days average trading volume of the share is 5,30,951.

As of today, Jubilant has a market cap of Rs 9884.99 crores. The Promoter holding pledged by the company is as low as 5.67. The share touched a 52 week high as well as a life time high of 727.00 on 1st December 2016. The life time low is Rs 3.46 made on 16th April 2001 and the 52 week high is Rs 275.65 touched on 18th January 2016.

Jubilant is one of the multibagger stocks recommended by Dynamic levels. Get the historical share price performance of the scrip at Jubilant share price history.

Jubilant bags approval for Rosuvastatin Calcium Tablets

Jubilant Life Sciences Ltd which is an integrated global Pharmaceutical and Life Sciences Company, has announced that it has bagged Abbreviated New Drug Application (ANDA) final approval for Rosuvastatin Calcium Tablets, 5 mg, 10 mg, 20 mg as well as 40 mg, the generic version of Crestor of IPR Pharmaceuticals, which is used for the treatment of hyperlipidemia or mixed dyslipidemia.

The Company has received 7 approvals from the USFDA during the year. As on 30^th September, 2016, Jubilant Life Sciences had a total of 72 ANDAs for Oral Solids filed in the US, of which 47 have been approved.

Jubilant share price is currently trading at Rs 694.2, up by Rs 7.25 or 1.06 per cent from its previous closing of Rs 686.95 on the Bombay Stock Exchange.

Jubilant share price opened at Rs 688 and has touched a high and low of Rs 705.05 and Rs 671.05 respectively. So far 1069447(NSE and BSE) shares were traded on the counter. The current market cap of the company is Rs 10943.11 crores.

The BSE group 'A' stock has a face value Re 1 and has touched a 52 week high of Rs 700.9 on 19^th October 2016 and a 52 week low of Rs 272.5 on 20^th January 2016. Last one week high and low of the share stood at Rs 698 and Rs 637.5 respectively.

The promoters holding in the company stood at 54.02 per cent while Institutions and Non-Institutions held 26.26 per cent and 17.34 per cent respectively. Jubilant is a multibagger, as per Dynamic Levels Researchers.

Jubilant Life Sciences Ltd is an integrated global pharmaceutical as well as life sciences company engaged in manufacturing and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products, Advance Intermediates, Fine Ingredients, Crop Science Ingredients, and Life Science Chemicals along with Nutritional Products. It also provides services in Contract Manufacturing of Sterile Injectables and Drug Discovery Solutions. The firm’s strength lies in its unique offerings of Pharmaceutical and Life Sciences products and services.

Source: www.dynamiclevels.com

Jubilant’s Subsidiary Raises $ 300 Mn through Bonds

Today, Jubilant Life Sciences announced that its subsidiary Jubilant Pharma had raised $300 million (approx Rs. 1,998 crores) through the issuance of five-year bonds to mainly retire debts. The announcement has given a little push to the Jubilant share price.

Their material wholly-owned subsidiary, Jubilant Pharma Ltd, has effectively completed the pricing of its rated unsecured high yield bonds (Notes) at a deferment of 4.875 per cent per annum. The bonds were issued at par for $300 million and will be maturing in September 2021.

Jubilant said that the net proceeds of the Notes should be used to prepay the on hand debt of Jubilant Pharma and its subsidiaries. It will also be used for up-streaming up to $50 million to Jubilant Life Sciences for prepayment of its existing debts and general corporate purposes.

Jubilant share price went as high as 3.4% intraday to trade at Rs. 610.30 while its intraday low stands at 587.40 so far. By 1:00 PM, over five lakhs shares were traded on the NSE counter against an average of 15.56 lakhs shares for twenty days. The company has the PE of 101.41 and the market cap of 9403.96 crores as on date. Jubilant has the turnover of 4.74 crores and 8.16% promoter holding pledged.

Jubilant share price of face value Re. One traded at the 52 weeks high and the lifetime high of Rs. 654.75 on 27th September 2016. The stock traded at the 52-weeks low of Rs. 275.65 on 18th January 2016 and the lifetime low of Rs. 3.46 on 16th April 2001.

Jubilant is the Multibagger stock of the month by Dynamic Levels. Its previous close of Rs. 590.40 is close to its major support level of Rs. 575.25, while the stock’s closest resistance stands at Rs. 643.95. For more levels of support and resistance of Jubilant, visit Jubilant share price forecast page of Dynamic Levels website.

Jubilant Life Sciences Ltd: Out-performer in Pharma Sector

Jubilant Life Sciences Ltd is a globally integrated Pharmaceutical and Life Sciences Company operating in manufacture and supply of Application Programming Interfaces (APIs), Radio pharmaceuticals,Solid Dosage Formulations, Allergy Therapy Products and Life Science Ingredients. In addition, it provides services in Contract Manufacturing of Sterile Injectables and Drug Discovery Solutions. It has opened up prospects in the Drug Discovery Solutions Segment by conducting collaborative and integrated programs. The strength of the Company lies in its unique Pharmaceuticals and Life Sciences products and services offered across the value chain.

Jubilant Life Sciences shares surged over 3% on Tuesday, 9th August, and showed strong profitability as it posted a 22.48% rise in consolidated net profit in its FY17 Q1 results on grounds of improved performance of specialty pharmaceuticals and reduction in expenses. Jubilant share price settled 3.61 per cent up at Rs 341.90. The stock opened at Rs 327.75 and reached a high and low of Rs 348.45 and Rs 327.75, respectively, in trade on the result day.

Key Highlights 

• The consolidated revenue stands at Rs.1420 crores with international revenues contributing 74% to the overall mix.
• PAT was reported at Rs.162 crores which is a 22% YoY rise.
• The total revenue has shown a QoQ decline in addition to a rise in expenditure. However, the operating profit has shown an increase which is justified by cost optimisation practices.
• EBITDA was Rs. 372 Crore, improving by 13% YoY with EBITDA margins at 26.2%, up from 22.7% in Q1’16.
• The EPS of the consolidated entity rose to 10.15 in comparison to 3.03 QoQ. However, this huge upshot can to attributed to the presence of an exceptional item in the previous quarter which deals with changes in the fair value of investments and profit on sale of investments.
• Capital expenditure was Rs.41 crores and net debt reduction was Rs.247 crores. The company further aims to reduce debt in the time to come.
• On a standalone basis, the profit after tax recovered from a negative Rs.7.47 crores to positive Rs.20.98 crores with an almost 50% reduction in taxes.

Segment Wise Review

Pharmaceuticals

• This segment reported revenues of Rs.752 crores, depicting a 7% YoY rise. Specialty Pharmaceuticals (Sterile Products) revenues rose 13% YoY, constituting 54% of total Pharmaceuticals segment sales.
• EBITDA growth was 13% YoY with a 34% margin, compared to 32.2% in Q1 FY16; aided by improvement in Specialty Pharmaceuticals (Sterile Products).
• It contributed 70% to the company’s EBITDA.
• There was an addition of one new client in the quarter in CMO of sterile injectibles with an order book of $534 million.

Life Science Ingredients

• Revenues in this segment have seen a 14% YoY decline while EBITDA margins have gone up from 17.2% in Q1 FY 16 to 19% in Q1 FY 17. This is attributed to its its cost optimization initiatives.
• Primary reasons behind the revenues decline are lower input prices due to lower crude prices consequently resulting in a decline in prices of finished products and emphasis on some profitable markets.

Drug Discovery Solutions

• Revenues grew 102% YoY, contributing 3% to total revenues.
• The EBITDA margin saw a drastic increase from -3.5% in Q1 FY16 to 32.2% in Q1 FY17.
• There have been strategic investments in the Drug Discovery ventures.

Prospects

Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia,  Co-Chairman & MD, Jubilant Life Sciences put forward their outlook by stating ‘We are glad to state that our company has built a robust long term sustainable business model with the growth engine of Pharmaceuticals and Drug Discovery Solutions segments. By creating focused management teams for all the three segments of businesses, we are able to clearly define strategic initiatives with the right mix of capital allocation. We believe that the company will continue to deliver better performance going forward given the robust product pipeline in place.’

The Board expects the company to retain momentum with its endeavors such as the new product launches in Generics, growth in ROW business, expected launches of its products such as Ruby-fill and other strategic initiatives for better capacity utilization.

With 11 world-class manufacturing facilities in India, US and Canada and a committed team of around 6500 multicultural people across the globe, the Company is dedicated to deliver value to customers spread across above 100 countries. The Company is recognized as a ‘Partner of Choice’ by leading pharmaceuticals and life sciences companies at a global level.

Investment Opinion

Jubilant is a good buy at 350 which is the previous day low with the target of 410 as it has come out with excellent numbers and is still trading at a low PE of 12.6.

Jubilant has shown huge delivery quantity of 11.46 lakhs share (20 day Average delivery position is for 3.5 lakhs share) on 10th august were share traded in a range of Rs. 352 as low to Rs. 378 as high  of that day. There for Rs. 352 can be considered as a good support area to buy a stock if market gives correction.